Curis | CRIS - Gross Profit On Sales


Curis reported $1.14M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Curis USD 1.14M 8.86M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 688.84B 101.71B Mar/2026
TG Therapeutics USD 171.41M 16.98M Mar/2026
Verastem USD 14.64M 14.1M Dec/2025
Xoma 992K 846K Jun/2024